163 related articles for article (PubMed ID: 31628978)
21. The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome.
McCoubrey LE; Seegobin N; Sangfuang N; Moens F; Duyvejonck H; Declerck E; Dierick A; Marzorati M; Basit AW
J Control Release; 2024 May; 369():630-641. PubMed ID: 38599548
[TBL] [Abstract][Full Text] [Related]
22. Selective drug delivery to the colon using pectin-coated pellets.
He W; Qing D; Cao DY; Fan LF; Xiang B
PDA J Pharm Sci Technol; 2008; 62(4):264-72. PubMed ID: 19174955
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery.
Sangalli ME; Maroni A; Zema L; Busetti C; Giordano F; Gazzaniga A
J Control Release; 2001 May; 73(1):103-10. PubMed ID: 11337063
[TBL] [Abstract][Full Text] [Related]
24. Composite film-coated tablets intended for colon-specific delivery of 5-aminosalicylic acid: using deesterified pectin.
Sriamornsak P; Nunthanid J; Wanchana S; Luangtana-Anan M
Pharm Dev Technol; 2003 Aug; 8(3):311-8. PubMed ID: 12901696
[TBL] [Abstract][Full Text] [Related]
25. A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems.
Shahdadi Sardo H; Saremnejad F; Bagheri S; Akhgari A; Afrasiabi Garekani H; Sadeghi F
Int J Pharm; 2019 Mar; 558():367-379. PubMed ID: 30664993
[TBL] [Abstract][Full Text] [Related]
26. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.
Stobaugh DJ; Deepak P; Thorpe M; Hannon B; Ehrenpreis ED
Inflamm Bowel Dis; 2013 Feb; 19(2):301-8. PubMed ID: 22644716
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release.
Moutaharrik S; Maroni A; Neut C; Dubuquoy C; Dubuquoy L; Foppoli A; Cerea M; Palugan L; Siepmann F; Siepmann J; Gazzaniga A
Eur J Pharm Biopharm; 2023 Feb; 183():13-23. PubMed ID: 36563887
[TBL] [Abstract][Full Text] [Related]
28. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
[TBL] [Abstract][Full Text] [Related]
29. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Støa-Birketvedt G; Florholmen J
Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
[TBL] [Abstract][Full Text] [Related]
30. Colon-specific drug delivery systems based on cyclodextrin prodrugs: in vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates.
Zou MJ; Cheng G; Okamoto H; Hao XH; An F; Cui FD; Danjo K
World J Gastroenterol; 2005 Dec; 11(47):7457-60. PubMed ID: 16437716
[TBL] [Abstract][Full Text] [Related]
31. Technology to obtain sustained release characteristics of drugs after delivered to the colon.
Hu Z; Kimura G; Ito Y; Mawatari S; Shimokawa T; Yoshikawa H; Yoshikawa Y; Takada K
J Drug Target; 1999; 6(6):439-48. PubMed ID: 10937289
[TBL] [Abstract][Full Text] [Related]
32. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy.
Hardy JG; Harvey WJ; Sparrow RA; Marshall GB; Steed KP; Macarios M; Wilding IR
J Clin Pharmacol; 1993 Aug; 33(8):712-8. PubMed ID: 8408731
[TBL] [Abstract][Full Text] [Related]
33. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis.
Gionchetti P; Venturi A; Rizzello F; Corbelli C; Fanti S; Ferretti M; Boschi S; Miglioli M; Campieri M
Aliment Pharmacol Ther; 1997 Aug; 11(4):679-84. PubMed ID: 9305475
[TBL] [Abstract][Full Text] [Related]
34. Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets.
Vemula SK; Veerareddy PR
Expert Opin Drug Deliv; 2013 Jan; 10(1):33-45. PubMed ID: 23199134
[TBL] [Abstract][Full Text] [Related]
35. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
Sandborn WJ
J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
[TBL] [Abstract][Full Text] [Related]
36. Use of spray-dried chitosan acetate and ethylcellulose as compression coats for colonic drug delivery: effect of swelling on triggering in vitro drug release.
Nunthanid J; Luangtana-anan M; Sriamornsak P; Limmatvapirat S; Huanbutta K; Puttipipatkhachorn S
Eur J Pharm Biopharm; 2009 Feb; 71(2):356-61. PubMed ID: 18762255
[TBL] [Abstract][Full Text] [Related]
37. N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats.
Mura C; Nácher A; Merino V; Merino-Sanjuan M; Carda C; Ruiz A; Manconi M; Loy G; Fadda AM; Diez-Sales O
Int J Pharm; 2011 Sep; 416(1):145-54. PubMed ID: 21723929
[TBL] [Abstract][Full Text] [Related]
38. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
[TBL] [Abstract][Full Text] [Related]
40. An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting.
Raghavan CV; Muthulingam C; Jenita JA; Ravi TK
Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):892-5. PubMed ID: 12130845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
